82
Participants
Start Date
August 31, 2007
Primary Completion Date
November 30, 2010
Study Completion Date
May 31, 2016
CDX-110 with GM-CSF
Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
Temozolomide
Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
Celldex Investigational Site, New York
Celldex Investigational Site, New York
Celldex Investigational Site, Amherst
Celldex Investigational Site, Philadelphia
Celldex Investigational Site, Charlottesville
Celldex Investigational Site, Durham
Celldex Investigational Site, Cleveland
Celldex Investigational Site, Orange
Celldex Investigational Site, Westlake
Celldex Investigational Site, Cleveland
Celldex Investigational Site, Cincinnati
Celldex Investigational Site, Saginaw
Celldex Investigational Site, Saginaw
Celldex Investigational Site, Lansing
Celldex Investigational Site, Evanston
Celldex Investigational Site, Chicago
Celldex Investigational Site, Houston
Celldex Investigational Site, San Antonio
Celldex Investigational Site, Salt Lake City
Celldex Investigational Site, Orange
Celldex Investigational Site, San Francisco
Celldex Investigational Site, Stanford
Celldex Investigational Site, Seattle
Celldex Investigational Site, San Francisco
Celldex Investigational Site, Stanford
Celldex Investigational Site, New Haven
Celldex Investigational Site, New Haven
Celldex Investigational Site, New Haven
Celldex Investigational Site, Gainesville
Celldex Investigational Site, Boston
Celldex Investigational Site, Hackensack
Celldex Investigational Site, Cincinnati
Celldex Investigational Site, Cincinnati
Celldex Investigational Site, West Chester
Lead Sponsor
Celldex Therapeutics
INDUSTRY